The European Medicines Agency has announced the appointment of the chair and vice-chair to its new, multidisciplinary Committee for Advanced Therapies (CAT).
The CAT brings together some of Europe’s top pharmaceutical experts to assess the quality, safety and efficacy of advanced therapy medicinal products and to follow scientific developments in the field.
The committee’s new chair, Dr Christian Schneider, said: “Our common goal is to establish the CAT as a strong and internationally highly recognised independent committee.
“A committee that fosters innovative medicines gathers scientific expertise and skills, whilst it collaborates effectively with the other scientific committees at the EMEA to perform top-level assessment in the best interest of patients.”
Both Dr Schneider and the committee’s new vice-chair, Dr Anneli Salmikangas, have contributed to the work of the EMEA with their expertise over many years.
Dr Schneider is a member of the Committee for Medicinal Products for Human Use, the Scientific Advice Working Party, and he also chairs the Biosimilar Medicinal Products Working Party.
Dr Salmikangas is the chair of the EMEA’s Cell-based Products Working Party and a member of the Biologics Working Party.
Copyright Press Association 2009